Daniel Mattson, MD
Neurology · Bridgeton, MONPI 1447237870
Payments from drug & device makers
Across 842 payments — averaging $567.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$93K
- SK Life Science, Inc.$93K
- Neurelis, Inc.$60K
- Eisai Inc.$50K
- UCB, Inc.$40K
- Greenwich Biosciences, Inc.$31K
- plus $110K from 24 others
Across 1 payment — averaging $290.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$290
What the payments were for
- Consulting fees$24,7085%
- Speaking & faculty fees$375,20083%
- Travel & lodging$28,8866%
- Food & beverage$22,2145%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 89 | $93,457 |
| SK Life Science, Inc. | 125 | $93,321 |
| Neurelis, Inc. | 85 | $59,806 |
| Eisai Inc. | 72 | $50,258 |
| UCB, Inc. | 105 | $40,247 |
| Greenwich Biosciences, Inc. | 41 | $31,294 |
| AbbVie(2 entities) | 195 | $29,209 |
| Sunovion Pharmaceuticals Inc. | 24 | $24,699 |
| Adamas Pharmaceuticals, Inc. | 7 | $22,842 |
| MDD US Operations, LLC | 22 | $19,772 |
| Catalyst Pharmaceuticals, Inc. | 8 | $6,447 |
| Livanova USA, Inc. | 10 | $2,282 |
| Medtronic(2 entities) | 18 | $1,882 |
| Neurocrine Biosciences, Inc. | 5 | $525 |
| Boston Scientific | 3 | $268 |
| Sanofi | 4 | $263 |
| E.r. Squibb & Sons, L.L.C. | 3 | $246 |
| Novartis | 7 | $241 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $136 |
| Bristol Myers Squibb | 2 | $133 |
| Biogen | 2 | $128 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| AstraZeneca | 1 | $97 |
| Axsome Therapeutics, Inc. | 1 | $83 |
| Pfizer | 5 | $81 |
| Upsher-smith Laboratories LLC | 1 | $29 |
| Lundbeck LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Argenx US, Inc. | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$118,052
- XCOPRI$79,132
- VALTOCO$58,587
- Fycompa$55,683
- GOCOVRI$41,626
- APTIOM$24,459
- Nayzilam$16,068
- Briviact$14,087
- Cenobamate$10,747
- XYWAV$5,337
- Fintepla$4,486
- VNS Therapy$1,855
- PERCEPT PC BRAINSENSE$1,031
- APOKYN$500
- INGREZZA$392
- ZEPOSIA$360
- ACTIVA$304
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$265
- NURTEC ODT$248
- UBRELVY$240
How this compares
$477,930 in reported general payments places this provider in the 90th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 119 | $757,090 |
| XcopriCenobamate | 222 | $329,545 |
| BriviactBrivaracetam | 117 | $216,896 |
| AptiomEslicarbazepine Acetate | 98 | $169,058 |
| GocovriAmantadine Hcl | 25 | $109,159 |
| IngrezzaValbenazine Tosylate | 12 | $105,552 |
| Lacosamide | 557 | $96,499 |
| FycompaPerampanel | 55 | $82,897 |
| Rufinamide | 26 | $82,872 |
| VimpatLacosamide | 30 | $70,619 |
| NuplazidPimavanserin Tartrate | 14 | $69,049 |
| Levetiracetam | 985 | $52,356 |
| OnfiClobazam | 14 | $47,274 |
| NayzilamMidazolam | 27 | $44,360 |
| Rasagiline Mesylate | 114 | $31,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $40,247 | $331,875174 claims |
| SK Life Science, Inc.Xcopri | $93,321 | $329,545222 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $24,699 | $169,05898 claims |
| MDD US Operations, LLCGocovri | $19,772 | $109,15925 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $525 | $105,55212 claims |
| Eisai Inc.Fycompa | $50,258 | $82,89755 claims |
| Lundbeck LLCOnfi | $21 | $47,27414 claims |
| PfizerNurtec Odt, Dilantin, Dilantin | $81 | $33,35186 claims |
| AbbVieUbrelvy | $29,209 | $19,95116 claims |
| Upsher-smith Laboratories LLCTopiramate | $29 | $5,448241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 neurology providers in Missouri.
Other neurology in Bridgeton
- Siddharth KaulBridgeton$5.7M
- Seth HepnerBridgeton$406K
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Curtis SchreiberBolivar$6.4M
- Gregory WuSaint Louis$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.